300 high income jobs on offer in massive recruitment drive by Dei BioPharma

May 19, 2025 in Business, Companies, Science and Technology by Editor

Matugga-based Dei BioPharma has announced more than 300 positions, marking the start of a facility, is set to start in a couple of months’ time.

The jobs on offer and advertised recently in the Ugandan press, range from highly demanding technical positions that require high academic achievement, to simple support roles that require only a Uganda Certificate of Education. The call represents the single largest recruitment exercise in Uganda’s recent history.

According to Dei BioPharma’s promoter Dr. Matthias Magoola, the recruitment drive attests to how investment in strategic sectors can create high-value jobs and open opportunities in the country for many of Uganda’s academically accomplished but unemployed graduates.

“We are happy to reach a key milestone in this project, where we can now open doors to Uganda’s talented youth. There is something for everybody’ here and our projections are that we shall need as many as 40,000 highly skilled workers, once all the production elements are up and running,” Magoola says.

While Uganda’s tertiary institutions churn out high numbers of qualified graduates in technical fields, opportunities are limited. Many end up looking for opportunities abroad, resulting in brain-drain, or engage in other occupations that are not exactly aligned with their training.  Magoola says in both cases, this is a loss to the country because it does not get the full value of the resources invested in educating its’ people.  It is also a steep sacrifice for many poor parents who give all they can, to give their children a tertiary education in hope of a better future.

The initial batch of 300 workers being hired will operate the first two production lines that have been completed and certified by the National Drug Authority (NDA). Abiaz Rwamwiri, the NDA spokesperson recently told regional media that the authority had given Good Manufacturing Practices (GMP) Certificates to Dei Biopharma’s manufacturing lines for tablets and capsules.  Magoola says the lines will produce Penicillin and Cephalexin based anti-biotics.

In the pharmaceutical industry, Good Manufacturing Practices or GMP, is a system for protecting consumer safety that requires manufacturers to adhere to strict procedures and guidelines, designed to ensure that drugs are produced to a consistent quality and a controlled process to meet specific standards.

An advanced biotech lab for research and development of new products is also operational.

Besides the facility at Matugga, Dei BioPharma has also constructed and Active Pharmaceutical Ingredient Plant (API) in Kamuli District, that will produce medical grade starch from cassava, a key ingredient in drug production.

Construction of the ambitious production complex was launched by President Museveni and his Kenyan counterpart President William Ruto in July 2021. Once fully established the Matugga facility, set in more than 150 acres will have 12 separate production plants for manufacture of medical devices such as diagnostic text-kits, vaccines, veterinary drugs and advanced treatments for degenerative diseases such as cancer, Alzheimer and diabetes.